Skip to main navigation

Investor Relations

Overview
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Investor Resources

Press Releases

Year

1/2/2025

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Read More

Investor Contact

Helen Rubinstein

drafts investors@neumoratx.com

phone_iphone Main Line: (857) 760-0900

Subscribe to our Email Alerts

© Neumora Therapeutics, Inc.

btn >> Footer icons

Search Investors

Search this site